NCT07189624Not yet recruiting
Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 31 Dec 2025
Brief summary (registry, in English)
The main purpose of the study is to characterize the production of hepatokines (FGF21 and Follistatin) in response to a submaximal exercise on an ergocycle, in patients with hepatocellular carcinoma. The effect of exercise on hepatokines and metabolites production in liver cancer patients is not known. Studying this production could help to provide relevant recommendations for training programming in these patients.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 16 May 2025
- Start date
- Dec 2025
- Primary completion date
- Apr 2028
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07189624
What you commit to
- Study type: Interventional
- Planned participants: 12
- From Dec 2025 to the primary completion date, Apr 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Surgery performed within 30 days prior to inclusion visit
- Liver transplant
Other
- Hepatic encephalopathy grade II or higher
- Bone metastasis
- Muscle injury within 3 months of inclusion
- Pregnant or breast-feeding women
- Patients under legal protection (guardianship, curatorship, safeguard of justice)
- Participation in another clinical trial within 10 days of inclusion
Who the study is looking for
- Hepatocellular carcinoma developed on cirrhosis
- Cirrhosis of any etiology, defined by a liver elasticity measurement \>15kPa or a history of cirrhosis decompensation
- Hepatocellular carcinoma with indication for treatment by immunotherapy or chemoembolization
- Child-Pugh scores A and B7
- WHO score ≤ 2
- Affiliation to french national social security system
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Clermont-Ferrand Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Unknown status |
| Chu Estaing Medecine Digestive Et Hepatobiliaire Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.